Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > ASCO June 3-7
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(34)
•••
Comment by Wino115on May 09, 2022 11:52am
98 Views
Post# 34667173

RE:ASCO June 3-7

RE:ASCO June 3-7You're right that the annual is early June, so likely way too soon to present unless they are basically finished now and putting data and analysis together (but we haven't been told MTD). Looks like maybe there's a few associated ones and a gynecological one in Spain (how nice).








SPCEO1 wrote: I thought the ASCO conference (finally remembered the name of it) was in late June but it is actually in early June. So, a late breaker presentation there would certainly fit from a timing prespective but there might not be enough time to pull that off. I also wonder how often a phase 1a would be even considered for a late breaker - probably not too often I would imagine. They may be hustling just to get any data put together for this conference. But  if they can pull it off, we will not have to wait as long as I thought we would to hear any good news they share about phase 1a data.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities